Difference between revisions of "Cabazitaxel (Jevtana)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "[http://www.thomsonhc.com/home/dispatch Micromedex]" to "Micromedex") |
||
(4 intermediate revisions by 2 users not shown) | |||
Line 4: | Line 4: | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
− | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://reference.medscape.com/refdrug-srch/jevtana-cabazitaxel-999571 Medscape], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
Line 11: | Line 11: | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://products.sanofi.us/jevtana/jevtana.pdf Cabazitaxel (Jevtana) package insert]<ref name="insert"></ref> | *[http://products.sanofi.us/jevtana/jevtana.pdf Cabazitaxel (Jevtana) package insert]<ref name="insert"></ref> | ||
− | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/cabazitaxel.aspx Cabazitaxel (Jevtana) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/cabazitaxel.aspx Cabazitaxel (Jevtana) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/cabazitaxel-patient-drug-information Cabazitaxel (Jevtana) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cabazitaxel-patient-drug-information Cabazitaxel (Jevtana) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/cabazitaxel-patient-drug-information Cabazitaxel (Jevtana) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/cabazitaxel-patient-drug-information Cabazitaxel (Jevtana) patient drug information (UpToDate)]</ref> | ||
Line 20: | Line 20: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
− | *2011-03-17: Initial marketing authorization as Jevtana. | + | *2011-03-17: Initial marketing authorization as Jevtana. Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic [[prostate cancer]] previously treated with a docetaxel-containing regimen. ''(Based on TROPIC)'' |
==History of changes in Health Canada indication== | ==History of changes in Health Canada indication== | ||
*2011-06-06: Initial notice of compliance for the treatment of patients with castration resistant (hormone refractory) metastatic [[prostate cancer]] previously treated with a docetaxel containing regimen. | *2011-06-06: Initial notice of compliance for the treatment of patients with castration resistant (hormone refractory) metastatic [[prostate cancer]] previously treated with a docetaxel containing regimen. | ||
Line 26: | Line 26: | ||
*2014-07-04: Initial approval for the treatment of [[prostate cancer]]. | *2014-07-04: Initial approval for the treatment of [[prostate cancer]]. | ||
==Also known as== | ==Also known as== | ||
− | *'''Code names:''' | + | *'''Code names:''' XRP-6258, TXD-258, RPR-116258A |
*'''Brand names:''' Cabapan, Cabaxan, Cabazither, Cabtana, Cazat, Jevatax, Jevtana, Kabanat, Procabazi, Qtervaxia, Z-Texel | *'''Brand names:''' Cabapan, Cabaxan, Cabazither, Cabtana, Cazat, Jevatax, Jevtana, Kabanat, Procabazi, Qtervaxia, Z-Texel | ||
Latest revision as of 01:50, 29 June 2024
General information
Class/mechanism: Taxane, promotes assembly of microtubules, stablizes microtubules, preventing depolymerization, inhibiting interphase/mitosis processes.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Cabazitaxel (Jevtana) package insert[1]
- Cabazitaxel (Jevtana) patient drug information (Chemocare)[4]
- Cabazitaxel (Jevtana) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2010-06-17: Initial approval in combination with prednisone for treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen. (Based on TROPIC)
- 2017-09-14: Approved at a lower dose (20 mg/m2 every 3 weeks) in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. (Based on PROSELICA)
- 2020-12-18: Approved in combination with prednisone for treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen. (Based on CARD)
History of changes in EMA indication
- 2011-03-17: Initial marketing authorization as Jevtana. Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. (Based on TROPIC)
History of changes in Health Canada indication
- 2011-06-06: Initial notice of compliance for the treatment of patients with castration resistant (hormone refractory) metastatic prostate cancer previously treated with a docetaxel containing regimen.
History of changes in PMDA indication
- 2014-07-04: Initial approval for the treatment of prostate cancer.
Also known as
- Code names: XRP-6258, TXD-258, RPR-116258A
- Brand names: Cabapan, Cabaxan, Cabazither, Cabtana, Cazat, Jevatax, Jevtana, Kabanat, Procabazi, Qtervaxia, Z-Texel